Back to News
Market Impact: 0.55

Japfa Comfeed Q1 2025 slides: stable growth amid strong Ramadan demand

Emerging MarketsCorporate EarningsCorporate Guidance & OutlookCompany FundamentalsConsumer Demand & RetailCommodities & Raw Materials
Japfa Comfeed Q1 2025 slides: stable growth amid strong Ramadan demand

PT Japfa Comfeed Indonesia (JPFA) reported stable Q1 2025 results, with revenue up 2.9% to IDR 14,332 billion and net profit increasing 5.5% to IDR 754 billion, driven by Ramadan demand. The company, Indonesia's second-largest poultry feed and DOC producer, has strengthened its balance sheet, reducing its Net Debt/Equity ratio from 78.9% to 52.5%. JPFA is focused on downstream expansion, aquaculture development, and its vaccine business to capitalize on Indonesia's growing protein consumption, which lags regional peers.

Analysis

PT Japfa Comfeed Indonesia Tbk (JPFA) demonstrated stable financial performance in Q1 2025, underscored by a 2.9% year-over-year revenue increase to IDR 14,332 billion and a more pronounced 5.5% rise in net profit to IDR 754 billion, largely attributed to heightened demand during the Ramadan period. This modest growth was accompanied by a significant strengthening of its financial position, evidenced by a reduction in the Net Debt/Equity ratio from 78.9% in March 2024 to 52.5% in March 2025, and a decrease in total interest-bearing debt to IDR 10,819 billion. As Indonesia's second-largest producer of poultry feed (21% market share) and day-old chicks (25% market share), JPFA is strategically positioned within a market characterized by substantial long-term growth potential, given Indonesia's per capita poultry consumption of 8.3 kg lags significantly behind regional peers. The company's vertically integrated model, spanning feed production to consumer products, and its cost-plus pricing strategy provide operational efficiencies and a mechanism to mitigate commodity price volatility. JPFA's articulated growth strategy, focused on downstream expansion, aquaculture development, and its Vaksindo vaccine business, alongside carefully managed capital expenditure (IDR 381 billion in Q1 2025), signals a clear path to capitalize on these opportunities while navigating cyclical market conditions. The reported sentiment for this update is strongly positive, reflecting confidence in JPFA's operational resilience and strategic direction.

AllMind AI Terminal